Provider-prescribed compounded tirzepatide microdosing for women focused on weight maintenance during midlife. Not for active weight loss. Compounded tirzepatide is not FDA-approved, and GLP-1 microdosing is not an FDA-approved dosing schedule. An $80 consult fee may apply if you don’t move forward after provider review.
Josie offers compounded tirzepatide (GLP-1 + GIP microdosing for women in perimenopause, menopause, or postmenopause who are focused on weight maintenance.
This is not a full-dose weight management plan.
Microdosing may be considered for women who are already at or near their goal weight, have healthy habits in place, or want provider-led support after reaching a weight goal.
A licensed provider reviews your intake, health history, current medications, goals, and eligibility before deciding whether treatment is appropriate.
Completing the intake form does not guarantee a prescription.
GLP-1 microdose tirzepatide may be considered for women who want provider-led support for weight maintenance during midlife.
This may include women who:
This option is not intended for women seeking active weight loss.
Women looking for provider-led weight management support should review Josie’s full-dose personalized GLP-1 injectable care path instead.
A licensed provider can help determine which care path may be appropriate after reviewing your intake and health history.
Answer questions about your health history, medications, goals, and current needs.
A licensed provider reviews your intake and determines whether microdose tirzepatide may be appropriate.
A prescription is only issued if your provider determines treatment is medically appropriate.
If prescribed, your medication is prepared and shipped by a U.S. compounding pharmacy.
Josie includes provider messaging and ongoing support so you can ask questions and stay connected to care.
If your intake is reviewed by a provider and you decide not to move forward with treatment after your consultation, an $80 consult fee may apply.
There is no separate $80 consult fee if you move forward with the prescribed medication.
Compounded tirzepatide is not FDA-approved. The FDA has not evaluated compounded medications for safety, effectiveness, or quality.
GLP-1 microdosing is not an FDA-approved dosing schedule or protocol and may involve lower doses than FDA-approved prescribing schedules.
GLP-1 medications are prescription medications and should only be used under the supervision of a licensed healthcare provider.
GLP-1 medications may carry serious risks and may not be appropriate for everyone. Your provider will review your health history, medications, goals, and possible risks before making a prescribing decision.
Josie is not a compounding pharmacy. If prescribed, medication is prepared and shipped by a U.S. compounding pharmacy.
No. Josie positions GLP-1 microdosing for weight maintenance support, not active weight loss.
Compounded tirzepatide microdosing is a lower-dose approach that may be considered by a licensed provider for maintenance-focused care.
No. GLP-1 microdosing is not an FDA-approved dosing schedule or protocol.
No. Compounded tirzepatide is not FDA-approved. The FDA has not evaluated compounded medications for safety, effectiveness, or quality.
Yes. This product is the month-to-month GLP-1 Microdose Tirzepatide plan.
No. Completing the intake form does not guarantee a prescription. A licensed provider determines whether treatment is appropriate.
No. Josie is not a compounding pharmacy. If prescribed, medication is prepared and shipped by a U.S. compounding pharmacy.
A licensed provider reviews your intake, health history, current medications, goals, and eligibility before deciding whether treatment is appropriate.
If your intake is reviewed and you decide not to move forward with treatment after your consultation, an $80 consult fee may apply. There is no separate $80 consult fee if you move forward with the prescribed medication.
Complete your intake so a licensed provider can review whether compounded tirzepatide microdosing may be appropriate for your health history and goals.
Josie offers compounded tirzepatide (GLP-1 + GIP microdosing for women in perimenopause, menopause, or postmenopause who are focused on weight maintenance.
This is not a full-dose weight management plan.
Microdosing may be considered for women who are already at or near their goal weight, have healthy habits in place, or want provider-led support after reaching a weight goal.
A licensed provider reviews your intake, health history, current medications, goals, and eligibility before deciding whether treatment is appropriate.
Completing the intake form does not guarantee a prescription.
GLP-1 microdose tirzepatide may be considered for women who want provider-led support for weight maintenance during midlife.
This may include women who:
This option is not intended for women seeking active weight loss.
Women looking for provider-led weight management support should review Josie’s full-dose personalized GLP-1 injectable care path instead.
A licensed provider can help determine which care path may be appropriate after reviewing your intake and health history.
Answer questions about your health history, medications, goals, and current needs.
A licensed provider reviews your intake and determines whether microdose tirzepatide may be appropriate.
A prescription is only issued if your provider determines treatment is medically appropriate.
If prescribed, your medication is prepared and shipped by a U.S. compounding pharmacy.
Josie includes provider messaging and ongoing support so you can ask questions and stay connected to care.
If your intake is reviewed by a provider and you decide not to move forward with treatment after your consultation, an $80 consult fee may apply.
There is no separate $80 consult fee if you move forward with the prescribed medication.
Compounded tirzepatide is not FDA-approved. The FDA has not evaluated compounded medications for safety, effectiveness, or quality.
GLP-1 microdosing is not an FDA-approved dosing schedule or protocol and may involve lower doses than FDA-approved prescribing schedules.
GLP-1 medications are prescription medications and should only be used under the supervision of a licensed healthcare provider.
GLP-1 medications may carry serious risks and may not be appropriate for everyone. Your provider will review your health history, medications, goals, and possible risks before making a prescribing decision.
Josie is not a compounding pharmacy. If prescribed, medication is prepared and shipped by a U.S. compounding pharmacy.
No. Josie positions GLP-1 microdosing for weight maintenance support, not active weight loss.
Compounded tirzepatide microdosing is a lower-dose approach that may be considered by a licensed provider for maintenance-focused care.
No. GLP-1 microdosing is not an FDA-approved dosing schedule or protocol.
No. Compounded tirzepatide is not FDA-approved. The FDA has not evaluated compounded medications for safety, effectiveness, or quality.
Yes. This product is the month-to-month GLP-1 Microdose Tirzepatide plan.
No. Completing the intake form does not guarantee a prescription. A licensed provider determines whether treatment is appropriate.
No. Josie is not a compounding pharmacy. If prescribed, medication is prepared and shipped by a U.S. compounding pharmacy.
A licensed provider reviews your intake, health history, current medications, goals, and eligibility before deciding whether treatment is appropriate.
If your intake is reviewed and you decide not to move forward with treatment after your consultation, an $80 consult fee may apply. There is no separate $80 consult fee if you move forward with the prescribed medication.
Complete your intake so a licensed provider can review whether compounded tirzepatide microdosing may be appropriate for your health history and goals.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript